Welcome to our dedicated page for INTELGENX TECHS news (Ticker: IGXT), a resource for investors and traders seeking the latest updates and insights on INTELGENX TECHS stock.
IntelGenx Technologies Corp., based in Montreal, is dedicated to developing innovative proprietary technologies for enhanced drug delivery. The company's business strategy involves leveraging these technologies to enhance existing drug compounds with proven efficacy and safety. Through collaborations with strategic partners, IntelGenx reintroduces these compounds to the market as branded products with improved deliverability and efficacy. The company offers full-service pharmaceutical development, including formulation, clinical development, regulatory activities, manufacturing, and packaging. IntelGenx's experienced team works with both new chemical entities and established therapeutic active pharmaceutical ingredients, utilizing innovative drug delivery systems for a competitive edge and product extension opportunities.
Rhea-AI Summary
IntelGenx Technologies Corp. (IGX) reported a revenue of $318,000 for Q3-2023, with a net comprehensive loss of $2.5 million. Recent developments include receiving a purchase order for RIZAFILM® from Gensco Pharma, and completing patient enrollment for a clinical trial of Montelukast VersaFilm® in Alzheimer’s patients. The company also announced several other positive developments, including a research collaboration with Karolinska University Hospital for the treatment of Parkinson’s Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IntelGenx Corp. has announced a further amendment to their agreement with Tilray Brands Inc. for the co-development and commercialization of cannabinoid-infused VersaFilm® products. The amendment includes an initial purchase order for three SKUs totaling 130,000 filmstrips and allows for the co-development and commercialization of CBD, THC, and combination THC:CBD products with additional partners. The agreement also removes any royalties paid to or from Tilray.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IntelGenx Technologies Corp. will release its third quarter 2023 financial results on November 9, 2023, after market close. The accompanying conference call will be hosted by the CEO, President, and Chairman to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
Rhea-AI Summary
IntelGenx receives first purchase order for RIZAFILM® from Gensco Pharma, triggering upfront deposit and milestone payments. Expects to ship product in Q1-2024 for immediate launch. CEO expresses confidence in partnership and positive impact on balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IntelGenx Corp. provides regulatory update on Buprenorphine Buccal Film. FDA grants priority review with goal date for review of the Amendment on March 8, 2024, unless inspection required. CEO optimistic about FDA decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IntelGenx Technologies Corp. announces closing of non-brokered private placement with atai Life Sciences AG for gross proceeds of approximately US$3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.75%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
Rhea-AI Summary
IntelGenx Corp. has completed patient enrollment in the Montelukast VersaFilm Phase 2a clinical trial for Alzheimer's Disease. The study enrolled 52 patients, 18 fewer than planned, with approval from Health Canada. The company aims to determine the extent of the drug's effect sizes and expects to complete the trial in Q1 2024 and report initial results in Q2 2024. The AD market is projected to reach $13.7 billion in 2030 with a compound annual growth rate of 20%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
FAQ
What is the current stock price of INTELGENX TECHS (IGXT)?
The current stock price of INTELGENX TECHS (IGXT) is $0.167 as of May 16, 2024.
What is the market cap of INTELGENX TECHS (IGXT)?
The market cap of INTELGENX TECHS (IGXT) is approximately 29.7M.
What is the primary focus of IntelGenx Technologies Corp.?
IntelGenx is dedicated to developing innovative proprietary technologies for enhanced drug delivery.
How does IntelGenx enhance existing drug compounds?
The company leverages its proprietary drug delivery technologies to improve existing drug compounds with proven efficacy and safety.
What is IntelGenx's business strategy?
The company reintroduces enhanced drug compounds to the market as branded products with improved deliverability and efficacy through strategic partnerships.
What services does IntelGenx offer?
IntelGenx provides full-service pharmaceutical development, including formulation, clinical development, regulatory activities, manufacturing, and packaging.
What types of active pharmaceutical ingredients does IntelGenx work with?
IntelGenx works with both new chemical entities and established therapeutic active pharmaceutical ingredients.
What advantage do innovative drug delivery systems offer IntelGenx?
Innovative drug delivery systems provide significant competitive advantages and opportunities for product extension for IntelGenx.
Who can be contacted for investor relations at IntelGenx?
For investor relations, contact Stephen Kilmer at (647) 872-4849 or stephen@kilmerlucas.com.
Who is the President and CFO of IntelGenx Corp.?
Andre Godin is the President and CFO of IntelGenx Corp.
Where can copies of the SISP Order and procedures be obtained?
Copies of the SISP Order and procedures can be obtained from the website of the Monitor at www.ey.com/ca/intelgenx.
How can U.S. persons direct inquiries regarding IntelGenx?
U.S. persons should direct inquiries to Ernst & Young Corporate Finance (Canada) Inc. through Jatinder Wadhwa.
INTELGENX TECHS CORP